Salud financiera de hoja de balance de Sopharma AD

Salud financiera controles de criterios 5/6

Sopharma AD tiene un patrimonio de accionistas total de BGN752.8M y una deuda total de BGN263.0M, lo que sitúa su ratio deuda-patrimonio en 34.9%. Sus activos y pasivos totales son BGN1.5B y BGN757.1M respectivamente. El BAIT de Sopharma AD es de BGN92.6M, por lo que su ratio de cobertura de intereses es de 14. Tiene efectivo e inversiones a corto plazo que ascienden a BGN128.9M.

Información clave

34.9%

Ratio deuda-patrimonio

лв263.03m

Deuda

Ratio de cobertura de intereses	14x
Efectivo	лв128.88m
Patrimonio	лв752.81m
Total pasivo	лв757.08m
Activos totales	лв1.51b

Actualizaciones recientes sobre salud financiera

Sopharma AD (BUL:SFA) Has A Somewhat Strained Balance Sheet

Apr 09

Sopharma AD (BUL:3JR) Has A Somewhat Strained Balance Sheet

Jan 06

Recent updates

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo (BGN781.9M) de SFA superan a sus pasivos a corto plazo (BGN607.7M).

Pasivo a largo plazo: Los activos a corto plazo de SFA (BGN781.9M) superan a sus pasivos a largo plazo (BGN149.4M).

Historial y análisis de deuda-patrimonio

Nivel de deuda: El ratio deuda neta-patrimonio (17.8%) de SFA se considera satisfactorio.

Reducción de la deuda: El ratio deuda-patrimonio de SFA ha pasado de 63.1% a 34.9% en los últimos 5 años.

Cobertura de la deuda: La deuda de SFA no está bien cubierta por el flujo de caja operativo (17.1%).

Cobertura de intereses: Los pagos de intereses de la deuda de SFA están bien cubiertos por el BAIT (14x cobertura).

Salud financiera de hoja de balance de Sopharma AD

Salud financiera controles de criterios 5/6

Información clave

Actualizaciones recientes sobre salud financiera

Sopharma AD (BUL:SFA) Has A Somewhat Strained Balance Sheet

Sopharma AD (BUL:3JR) Has A Somewhat Strained Balance Sheet

Recent updates

Now 23% overvalued after recent price rise

Full year 2023 earnings: EPS and revenues exceed analyst expectations

New major risk - Revenue and earnings growth

Chairman recently sold лв527k worth of stock

Sopharma AD, Annual General Meeting, Jun 30, 2024

Chairman recently bought лв338k worth of stock

New major risk - Financial position

Third quarter 2023 earnings released: EPS: лв0.12 (vs лв0.20 in 3Q 2022)

Upcoming dividend of лв0.90 per share at 8.4% yield

Sopharma AD Approves Distribution for the First Half of 2023, Payable on January 22, 2024

New minor risk - Share price stability

Sopharma AD to Report Q3, 2023 Results on Nov 29, 2023

New minor risk - Shareholder dilution

Chairman recently bought лв72k worth of stock

Investor sentiment improves as stock rises 17%

Sopharma AD to Report Q3, 2023 Results on Oct 30, 2023

Chairman recently bought лв81k worth of stock

Chairman recently sold лв1.1m worth of stock

Sopharma AD (BUL:SFA) acquired a 2.38% stake in Sopharma Buildings REIT-Sofia.

Second quarter 2023 earnings released: EPS: лв0.25 (vs лв0.19 in 2Q 2022)

New minor risk - Shareholder dilution

Sopharma AD (BUL:SFA) signed an agreement to acquire Pharmanova d.o.o.

Chairman recently sold лв297k worth of stock

New minor risk - Dividend sustainability

Upcoming dividend of лв0.60 per share

Sopharma AD Declares Dividend for 2022, Payable on 31 July 2023

First quarter 2023 earnings released: EPS: лв0.27 (vs лв0.17 in 1Q 2022)

Full year 2022 earnings: EPS exceeds analyst expectations

Sopharma AD, Annual General Meeting, Jun 30, 2023

Sopharma AD to Report Fiscal Year 2023 Results on Mar 29, 2024

Consensus EPS estimates increase by 83%

Price target increased to лв4.83

Third quarter 2022 earnings released: EPS: лв0.20 (vs лв0.14 in 3Q 2021)

Less than half of directors are independent

Second quarter 2022 earnings released: EPS: лв0.19 (vs лв0.12 in 2Q 2021)

Sopharma AD (BUL:SFA) made the offer to acquire remaining 66.66% stake in Sopharma Properties REIT (BUL:SFI) for approximately BGN 120 million.

First quarter 2022 earnings released: EPS: лв0.17 (vs лв0.14 in 1Q 2021)

Sopharma AD, Annual General Meeting, Jun 03, 2022

Less than half of directors are independent

Sopharma AD to Report Fiscal Year 2021 Final Results on Apr 29, 2022

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Sopharma AD to Report Fiscal Year 2021 Results on Mar 31, 2022

An unknown buyer has agreed to acquire SIA BRIZ from Sopharma AD (BUL:SFA).

Third quarter 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Second quarter 2021 earnings released

Chairman recently bought лв79k worth of stock

Price target decreased to лв3.48

Price target decreased to лв3.48

First quarter 2021 earnings released

Sopharma AD (BUL:SFA) Has A Somewhat Strained Balance Sheet

Full year 2020 earnings released: EPS лв0.20 (vs лв0.69 in FY 2019)

New 90-day high: лв3.50

Here's Why We Think Sopharma AD (BUL:3JR) Is Well Worth Watching

How Many Sopharma AD (BUL:3JR) Shares Do Institutions Own?

Should You Rely On Sopharma AD's (BUL:3JR) Earnings Growth?

New 90-day high: лв3.26

Sopharma AD (BUL:3JR) acquired an unknown minority stake in SIA BRIZ.

Sopharma AD (BUL:3JR) Has A Somewhat Strained Balance Sheet

An unknown buyer acquired majority stake of Aromania OOD from Sopharma AD (BUL:3JR).

Sopharma AD (BUL:3JR) Share Prices Have Dropped 25% In The Last Three Years

New 90-day high: лв3.18

Should Sopharma AD (BUL:3JR) Be Part Of Your Dividend Portfolio?

Are Investors Undervaluing Sopharma AD (BUL:3JR) By 29%?

New 90-day high: лв3.16

Price target lowered to лв3.24

Should Sopharma AD (BUL:3JR) Be Part Of Your Dividend Portfolio?

Análisis de la situación financiera

Historial y análisis de deuda-patrimonio

Hoja de balance

Descubre empresas con salud financiera